SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Serina Therapeutics Q3 net loss attributable to common stockholders widens 68% to $7.9 million

Serina Therapeutics Q3 net loss attributable to common stockholders widens 68% to $7.9 million S

SER

Related stories